Boston Cambridge Biotech Networks’ Post

Charles River Laboratories and Sanofi have joined forces to revolutionize preclinical research by introducing virtual control animals in place of live subjects. By utilizing historical control data, virtual control groups (VCGs) aim to streamline research processes by eliminating the need for live animals in control groups. Through a blend of machine learning and toxicology, Charles River will spearhead the development of VCG models under the Alternative Methods Advancement Project, a groundbreaking initiative in animal testing alternatives. This collaboration signifies a pivotal shift towards more ethical and efficient research practices in the pharmaceutical industry. #PreclinicalResearch #Innovationhttps://buff.ly/3Ky5qip

Weight of Evidence (WOE) approaches are a valuable 3Rs-based method for determining whether standard nonclinical toxicology studies are necessary to characterize the safety risks of a new drug. In some cases, a thorough review of a drug's mechanism of action, target biology, and disease pathogenesis may provide sufficient data for risk assessment without the need for additional animal studies. A new paper in #IJT offers industry and regulatory perspectives on using a WOE approach for carcinogenicity, drug abuse liability, and pediatric safety assessments. Check it out: https://lnkd.in/d4nihCN2   For the College's policy on the ethical treatment of animals in research, please see the ACT comprehensive policy statement at https://lnkd.in/eznYnkJf and please consider that other approaches might be available.

Our next 2023 milestone: Scaling up manufacturing for MyoTrim as we prepare for downstream toxicology studies. After confirming its efficacy in disease animal models, the crucial next step is expanding production from academic labs. This scaling up process is essential, ensuring we meet the quantity required for toxicology studies and eventual human dosing in clinical trials. #MuscularDystrophyResearch #CureRareDisease

In just two days, you can join our webinar about Göttingen Minipigs as a model in inhalation toxicity studies, where our specially invited speaker will share her knowledge on the topic. Read abstract and register here: https://lnkd.in/dPnSpkMs #EllegaardGöttingenMinipigs #GöttingenMinipigs #GöttingenMinipigsAcademy

Upcoming webinar from Ellegaard Göttingen Minipigs on "Göttingen Minipig as Animal Model for Inhalation Toxicity Studies". Read more and register here: https://lnkd.in/dPnSpkMs ...and share with your network! #EllegaardBioresearch #GöttingenMinipigs #GöttingenMinipigsAcademy

We are combining the science of #toxicology with the power of machine learning to drive greater adoption of VCGs and reduce the need for research animals across the industry. https://okt.to/JABe4m

For our next webinar, we have invited Manuela Teti to share her knowledge about "Göttingen Minipig as Animal Model for Inhalation Toxicity Studies". WHAT YOU WILL LEARN: Göttingen Minipigs, as a model for inhalation studies, provide a valuable alternative to dogs and nonhuman primates as non-rodent species in preclinical toxicology. This webinar highlights the use of minipigs in inhalation toxicology, exploring the ethical, scientific, and practical factors associated with this animal model. Minipigs present comparable lung structure, airway morphology, and respiratory mechanics to humans, which attest to their translational value and make them suitable for studying inhaled drug delivery and toxicological assessments of airborne substances. The session will cover operational practices of acclimatisation, training, dosing and health monitoring to ensure the highest levels of minipigs’ study compliance and animal welfare. It will provide insights into specialist equipment and technical staff requirements, highlighting aspects that characterise the use of this animal model in inhalation toxicology. The areas covered will provide participants with an overview of the robustness of minipigs as a non-rodent inhalation animal model. Read more and register here: https://lnkd.in/dPnSpkMs #EllegaardGöttingenMinipigs #GöttingenMinipigs #GöttingenMinipigsAcademy

Want to know more about how in vitro science is bridging the gap between animal testing and human results? This article goes into greater detail about our work with Charles River Laboratories to develop a New Approach Methodology (NAM) inhalation toxicology test to reduce reliance on traditional animal research methods. #betterscience #NAMs

Charles River Laboratories and Sanofi are breaking new ground with their latest initiative to introduce Virtual Control Animals (VCGs) in preclinical research. Announced on June 5, this project aims to revolutionize the industry by replacing live control animals with virtual ones, leveraging extensive historical data for more efficient and ethical studies. This initiative is part of Charles River’s broader $300 million, five-year Alternative Methods Advancement Project, launched in April, aimed at finding alternatives to animal testing. By combining machine learning and toxicology, this partnership with Sanofi is set to lead the way in humane and innovative research practices. #PreclinicalResearch #Innovation #EthicalScience #CharlesRiverLaboratories #Sanofi #VCGs #AlternativeMethods #AIInResearch #Toxicology #MachineLearning #LifeSciences #NAM #AnimalFree #CharlesRiver #Sanofi #Biomerieux #BoehringerIngelheim #Lyon #Organoid #Cancer #CNRS #Inserm #CLB #CRCL #LBTI #Proanima #3DCellCulture https://lnkd.in/exvthNak

Chief Scientist, J. Hickman, is presenting today at the Toxicology Forum which brings together regulatory agencies with industry and academia. His talk titled: "How Does Replacing or Augmenting Animal Studies with Microphysiological Systems Differ Between Efficacy and Safety?" will cover regulatory questions associated with integrating organ-on-a-chip technology in the drug discovery process. Learn more about the meeting here: https://buff.ly/3Ocz92P #Hesperos #FDA #ToxicologyForum #Innovation #DrugDiscovery #HumanOnAChip #OrganOnAChip #MicrophysiologicalSystems #DrugDiscovery